Pathophysiological features of coronavirus disease 2019-associated acute respiratory distress syndrome (COVID-19 ARDS) were indicated to be somewhat different from those described in nonCOVID-19 ARDS, because of relatively preserved compliance of the respiratory system despite marked hypoxemia. We aim ascertaining whether respiratory system static compliance (Crs), driving pressure (DP), and tidal volume normalized for ideal body weight (VT/kg IBW) at the 1st day of controlled mechanical ventilation are associated with intensive care unit (ICU) mortality in COVID-19 ARDS.
Methods
Observational multicenter cohort study. All consecutive COVID-19 adult patients admitted to 25 ICUs belonging to the COVID-19 VENETO ICU network (February 28th–April 28th, 2020), who received controlled mechanical ventilation, were screened. Only patients fulfilling ARDS criteria and with complete records of Crs, DP and VT/kg IBW within the 1st day of controlled mechanical ventilation were included. Crs, DP and VT/kg IBW were collected in sedated, paralyzed and supine patients.
Results
A total of 704 COVID-19 patients were screened and 241 enrolled. Seventy-one patients (29%) died in ICU. The logistic regression analysis showed that: (1) Crs was not linearly associated with ICU mortality (p value for nonlinearity = 0.01), with a greater risk of death for values < 48 ml/cmH2O; (2) the association between DP and ICU mortality was linear (p value for nonlinearity = 0.68), and increasing DP from 10 to 14 cmH2O caused significant higher odds of in-ICU death (OR 1.45, 95% CI 1.06–1.99); (3) VT/kg IBW was not associated with a significant increase of the risk of death (OR 0.92, 95% CI 0.55–1.52). Multivariable analysis confirmed these findings.
Conclusions
Crs < 48 ml/cmH2O was associated with ICU mortality, while DP was linearly associated with mortality. DP should be kept as low as possible, even in the case of relatively preserved Crs, irrespective of VT/kg IBW, to reduce the risk of death.
Annalisa Boscolo and Nicolò Sella have contributed equally to this work
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
COVID-19
Coronavirus disease 2019
ARDS
Acute respiratory distress syndrome
ICU
Intensive care unit
Crs
Static compliance of the respiratory system
DP
Driving pressure
VT/kg IBW
Tidal volume normalized for ideal body weight
CMV
Controlled mechanical ventilation
SOFA
Sequential organ failure assessment score
PaO2
Arterial partial pressure of oxygen
PaCO2
Arterial partial pressure of carbon dioxide
PEEP
Positive end-expiratory pressure
FiO2
Fraction of inspired oxygen
Background
Pathophysiological features of coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (COVID-19 ARDS) were indicated to be somewhat different from those described in nonCOVID-19 ARDS, because of relatively preserved compliance of the respiratory system despite marked hypoxemia [1, 2]. These preliminary observations led some authors to question the efficacy of lung protective ventilation in patients with COVID-19 ARDS and suggested that a less tight limitation of volume could be allowed while delivering mechanical ventilation to these patients [2]. Other authors, however, proposed that protective ventilation limiting volume and pressure should be applied also in COVID-19 ARDS [3]. While strong evidence showed that lung protective ventilation improves survival in nonCOVID-19 ARDS patients [4‐6], data are still lacking on COVID-19 ARDS patients.
In order to assess whether lung protective ventilation affects intensive care unit (ICU) mortality also in patients with COVID-19 ARDS, we set up a study to test the hypothesis that static compliance of the respiratory system (Crs), driving pressure (DP), and tidal volume normalized for ideal body weight (VT/kg IBW) are associated with ICU mortality.
Anzeige
Methods
This multicenter observational study was coordinated by Padua University Hospital (Italy), and followed the “Strengthening the Reporting of Observational Studies in Epidemiology” statement guidelines for observational cohort studies (Additional file 1) [7]. The study was approved by the Institutional Ethical Committee of each participating center (coordinator center approval reference number 4853AO20, while the full list of all approval reference numbers is available in Additional file 2) and informed consent was obtained according to the national regulation. Data were collected by the COVID-19 VENETO ICU Network, including 25 ICUs [8], and inserted into a pre-designed online data acquisition system (www.covid19veneto.it). Patients’ privacy was protected by assigning a de-identified patient code. Guidelines for management of mechanically ventilated patients had been provided to all ICUs of the regional network (from March 2nd, 2020) [8].
We included all consecutive adult patients with confirmed SARS-CoV-2 infection and fulfilling ARDS criteria [1], admitted between February 28th and April 28th, 2020, who received controlled mechanical ventilation (CMV), and had Crs, DP and VT/kg IBW measured in supine position, after sedation and paralysis, within the first 24 h of CMV. We excluded the patients with incomplete records, and those who had been prone positioned prior to data collection. COVID-19 diagnosis was made according to the WHO interim guidance (http://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf).
The following variables were collected: (1) demographic data (age, gender, body mass index); (2) Charlson comorbidity index not adjusted for age; (3) sequential organ failure assessment (SOFA) score at ICU admission; (4) gas exchange within the first 24 h of CMV [pH, arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)]; (5) ventilator settings [VT/kg IBW, respiratory rate, positive end-expiratory pressure (PEEP), fraction of inspired oxygen (FiO2)]; (6) plateau pressure, DP, Crs; and (7) ICU mortality.
Ventilator settings, plateau pressure, DP and Crs were collected within the first 24 h after endotracheal intubation in supine position on the basis of the senior attending physician’s assessment. The measurements were performed in sedated and paralyzed patients, with no spontaneous breathing activity. Patients were ventilated in volume-controlled mode. Plateau pressure and total PEEP were measured at zero flow point during end-inspiratory and end-expiratory pauses [5, 6]. DP was calculated as the difference between plateau pressure and total PEEP, while Crs was calculated as VT/DP [5, 6]. In the case of multiple determinations, the attending clinician in charge for the patients identified the most representative set of variables to be included in the analysis [14].
Anzeige
Prior to data analysis, two independent investigators and a statistician screened the database for errors against standardized ranges and contacted local investigators for any queries. Validated data were then entered into the final database. Patients transferred from one ICU to another were considered as a single case, while for those readmitted to ICU after discharge, only data from the first admission were considered.
Statistical analysis
Categorical data are presented as absolute numbers (n) and percentages (%). For continuous data, normality was tested by Skewness and Kurtosis tests. Means and standard deviations are used for normally distributed variables, while medians and interquartile ranges are used for non-normally distributed variables. No imputation for missing data has been planned. Logistic regression models have been estimated to assess the association between ICU mortality and Crs, DP, VT/kg IBW, total PEEP and plateau pressure. If the association was nonlinear, restricted cubic splines have been used to estimate the models and the change-point has been identified.
Additionally, multivariable logistic regression models have been used to evaluate the association between Crs and DP and ICU mortality after adjusting for relevant confounders. In each model, the independent predictors have been identified through a stepwise regression approach. This approach combines forward and backward selection methods in an iterative procedure (with a significance level of 0.05 both for entry and retention) to select predictors in the final multivariable model [9]. Independent variables used in the stepwise approach were age, gender, body mass index, SOFA score at ICU admission, Charlson comorbidity index, pH, PaO2/FiO2, PaCO2, ventilator settings (VT/kg IBW, respiratory rate, total PEEP) and plateau pressure at the first day of CMV. Additionally, collinearity has been defined for GVIF(1/(2×Df)) value greater than 2 [9, 10]. Variables with multicollinearity have been removed from the model (Additional file 3). Two different multivariable logistic regression models, one for Crs (model 1) and one for DP (model 2), were generated.
All statistical tests were 2-tailed, and statistical significance was defined as p < 0.05. All analyses have been conducted using R version 4.0.3 (R foundation for Statistical Computing, Vienna, Austria).
Results
During the study period, a total of 704 consecutive COVID-19 ARDS patients from 25 ICUs were included in the database. After excluding 463 patients, who did not receive CMV or did not fulfill ARDS criteria [1] or did not have complete records in supine position, 241 patients from 21 ICUs were deemed eligible for data analysis (Fig. 1).
×
Demographic and clinical characteristics of the study population are listed in Table 1.
Table 1
Clinical characteristics, respiratory parameters and outcomes of the study population
Overall population
n = 241
Clinical characteristics
Age (years)
66 [58–73]
Gender (male)
189 (78%)
SOFA score at ICU admission
5 [4–8]
BMI (kg/m2)
27 [25–30]
Charlson comorbidity index
1 [1, 2]
Onset of symptoms (days)
7 [3–9]
Hospital LOS before ICU (days)
2 [1–5]
Hospital LOS before CMV (days)
2 [1–5]
Gas exchange, at first day of CMV
pH
7.41 [7.36–7.46]
PaO2/FiO2 (mmHg)
142 [102–216]
PaCO2 (mmHg)
44 [38–52]
Ventilator settings and variables, at first day of CMV
Tidal volume (ml/kg of ideal body weight)
7.8 [6.9–8.8]
Set respiratory rates (breaths/min)
16 [14–20]
Total PEEP (cmH2O)
12 [10–13]
FiO2 (%)
60 [50–70]
Plateau pressure (cmH2O)
23 [20–26]
Driving pressure (cmH2O)
11 [9–13]
Static compliance of the respiratory system (ml/cmH2O)
48 [39–60]
Respiratory treatments before CMV
NIV failure
110 (46%)
HFOT failure
27 (11%)
None
104 (43%)
Adjunctive therapies during ICU stay
Prone position
202 (84%)
Neuromuscular blockers > 24 h
212 (88%)
V–V ECMO
5 (2%)
V–A ECMO
1 (0.4%)
Outcomes
ICU mortality
71 (29%)
60-day mortality
78 (32%)
Length of CMV (days)
12 [7–16]
ICU LOS (days)
15 [9–25]
Hospital LOS (days)
30 [18–41]
Data are expressed as median and interquartile range [IQR] or number (%)
SOFA sequential organ failure assessment, ICU intensive care unit, BMI body mass index, LOS length of stay, CMV controlled mechanical ventilation, PaO2 partial pressure of arterial oxygen, PaO2/FiO2 ratio between partial pressure of arterial oxygen and fraction of inspired oxygen, PaCO2 partial pressure of carbon dioxide, PEEP positive end-expiratory pressure, FiO2 fraction of inspired oxygen, NIV non-invasive ventilation, HFOT high flow oxygen therapy, V–V veno–venous, V–A veno–arterial, ECMO extracorporeal membrane oxygenation
On the first day of CMV, median Crs was 48 (39–60) ml/cmH2O, DP 11 (9–13) cmH2O and VT/kg IBW 7.8 [6.9–8.8) ml/kg. Seventy-one patients (29%) died in ICU.
The logistic regression analysis revealed a nonlinear relationship between Crs and ICU mortality (p value for nonlinearity = 0.01), with a significantly greater risk of death for values below 48 ml/cmH2O (Fig. 2A).
×
Anzeige
Contrariwise, a linear relationship between DP and ICU mortality (p value for nonlinearity = 0.68) was observed. An increase of DP from 10 to 14 cmH2O was associated with a 45% increment of the risk of ICU mortality (OR 1.45, 95% CI 1.06–1.99) (Fig. 2B). In addition, a linear relationship was also confirmed between ICU mortality and both total PEEP and plateau pressure (p value for nonlinearity = 0.22 both) (Additional file 4A, B).
VT/kg IBW was not associated with ICU mortality. Increasing VT/kg IBW from 6 to 8 ml/kg or from 8 to 10 ml/kg did not increase the risk of death (OR 0.92, 95% CI 0.55–1.52, for both ranges) (Fig. 2C).
Multivariable analysis confirmed Crs and DP to be independent risk factors for ICU mortality (OR 0.98, 95% CI 0.96–1.00, p = 0.03 and OR 1.12, 95% CI 1.00–1.24, p = 0.04, respectively) (Table 2).
Table 2
Multivariable models on the association between ICU mortality and static compliance of respiratory system (model 1) and driving pressure (model 2) at the first day of invasive controlled mechanical ventilation
OR (95% CI)
p value*
Model 1
Age (years)
1.10 (1.05–1.15)
< 0.01
Static compliance of the respiratory system (per ml/cmH2O increase)
0.98 (0.96–1.00)
0.03
Model 2
Age (years)
1.10 (1.05–1.15)
< 0.01
Driving pressure (per cmH2O increase)
1.12 (1.00–1.24)
0.04
Data are expressed as Odds ratio (OR) and 95% Confidence Interval (CI)
*Stepwise regression approach, combining forward and backward selection methods (with a significance level of 0.05 both for entry and retention), was applied to select predictors in the final multivariable model. Independent variables finally entered in the multivariable models were age, gender, body mass index, SOFA score at ICU admission, Charlson comorbidity index, PaO2/FiO2, PaCO2, VT/kg IBW and respiratory rate. Multicollinearity analysis is reported as Additional file 3
Discussion
We found that in COVID-19 ARDS patients (1) Crs has a nonlinear relationship with ICU mortality, with a greater risk of death for values below 48 ml/cmH2O; (2) DP is associated with ICU mortality, which increases linearly with DP increment; (3) VT/kg IBW is not a significant risk factor of ICU mortality.
Anzeige
In nonCOVID-19 ARDS patients, Crs failed to predict clinical outcomes, despite being associated with the functional lung size and the severity of the syndrome [5, 11]. A secondary analysis of the LUNG SAFE study, however, showed that lower Crs values, recorded on the first day of ARDS, were independently associated with mortality, even though the Crs–mortality relationship lacked a clear transition point and no useful cutoff could be established [9].
Wide ranges of Crs have been reported in COVID-19 ARDS patients [2, 12, 13], but the relationship between Crs and mortality remains uncertain [14, 15]. Grasselli et al. found that, among patients with COVID-19 ARDS, those who presented ‘low’ Crs within 24 h from ICU admission, associated with ‘high’ D-dimer concentration, had significantly greater 28-day mortality [14]. However, other studies were not able to confirm these results [13, 15].
We found Crs to be nonlinearly correlated with ICU mortality, with a significant association only for Crs values below 48 ml/cmH2O. This nonlinear relationship, which has already been reported in nonCOVID-19 ARDS patients [9], may depend on clinically relevant phenotypic heterogeneity [2, 3, 16, 17], and could explain the inconsistent results of previous investigations testing the association between Crs and mortality using a linear statistical approach [13‐15].
DP has been extensively studied in nonCOVID-19 ARDS patients and was associated with poor clinical outcomes [5, 6]. Indeed, in a post hoc observational study including 3562 ARDS patients, DP proved to be the variable that best stratified 60-day mortality risk, irrespective of PEEP, plateau pressure and VT/kg IBW [5]. Furthermore, the LUNG SAFE study, which enrolled 2377 intubated ARDS patients, showed that DP > 14 cmH2O on the first day of CMV is a risk factor of poor hospital survival [6]. For patients without ARDS, the effect of DP on the clinical outcome is still controversial [18‐20], though a meta-analysis including 2250 patients found that high DP during general anesthesia was associated with more postoperative pulmonary complications [21]. In COVID-19 ARDS patients, some cohort studies reported DP values quite close to those of nonCOVID-19 ARDS patients [12, 22], though the predictive role of DP on mortality remains unclear [13].
Anzeige
In our study FiO2 and PEEP were set according to the lower PEEP/FiO2 table [23]. It should be noted that PEEP settings were applied according to an official document released by the regional government and generated by consensus among clinicians of the ICU network, thus providing consistency and homogeneity to the data used for our analysis.
To the best of our knowledge, the present study is the first investigation finding a significant association between DP and mortality in COVID-19 ARDS patients receiving CMV. This linear relationship suggests that every effort should be made to reduce DP as much as possible, also in patients with relatively preserved Crs values. If, on the one hand, this is quite easy to accomplish when Crs is relatively preserved, on the other hand, when Crs is low, extracorporeal CO2 removal may be necessary to achieve this goal. Interestingly, the effect of DP on ICU mortality seems to be independent from VT/kg IBW, whose increment above the traditional cutoff value [4] did not affect patient outcome. Similar results have been recently reported in nonCOVID-19 ARDS patients by a post hoc secondary analysis of 5 randomized trials, including 1096 classical ARDS patients, which found that the benefit of lower tidal volumes (4–8 ml/kg IBW) on 60-day mortality was related to respiratory system elastance, suggesting that lung-protective ventilation strategies should primarily target driving pressure rather than tidal volume [24].
Our study has limitations. First, like the vast majority of the studies published during COVID-19 pandemic, it is an observational study, suffering the limits of this design. Second, we measured Crs and DP, which include the mechanical properties of the chest wall, in addition to those of the lung. Worth mentioning, however, a recent meta-analysis showed that more sophisticated respiratory parameters did not add important information on the risk of death in comparison to DP [25]. Third, our findings focus only on respiratory variables collected within the first day of CMV, while subsequent measurements during ICU stay were not considered. Although this approach has already been used by several published papers [6, 9, 14], it fails exploring the role of further clinical evolution after the first day. Moreover, the lead-time bias in the form of time period for which patients fulfilled ARDS criteria [1] or had ARDS before the assessment on the first day of CMV remains an unmeasured confounder [9]. Fourth, although regional guidelines proposed standardized ventilatory settings that were overall accepted [8], we cannot exclude for sure that some deviations from the indications occurred. Lastly, several patients were excluded for incomplete records, which depended on the overwhelming workload for ICU physicians during the COVID-19 pandemic making data recording problematic, especially in hospitals not included in the residency program.
Conclusions
In COVID-19 ARDS patients receiving CMV, ICU mortality is associated with Crs < 48 ml/cmH2O and linearly associated with DP. Our results suggest that DP should be kept as low as possible, irrespective of VT/kg IBW, to reduce the risk of death.
Acknowledgements
We are indebted with all ICUs personnel who made this work possible. Members of COVID-19 VENETO ICU Network, to be searchable through their individual PubMed records, are listed below: (1) U.O.C. Istituto di Anestesia e Rianimazione, Padova (Ilaria Valeri, MD; Giulio Andreatta, MD; Leonardo Gandolfi, MD; Alessandra Gadaldi, MD; Nicolò Brumana, MD; Edoardo Forin, MD; Christelle Correale, MD; Elisa Pesenti, MD; Davide Fregolent, MD; Pier Francesco Pirelli, MD; Davide Marchesin, MD; Matteo Perona, MD; Nicola Franchetti, MD; Michele Della Paolera, MD; Caterina Simoni, MD; Tatiana Falcioni, MD; Alessandra Tresin, MD; Chiara Schiavolin, MD; Aldo Schiavi, MD; Sonila Vathi, MD; Daria Sartori, MD; Alice Sorgato, MD; Elisa Pistollato, MD; Federico Linassi, MD); (2) Azienda Ospedale-Università di Padova, Padova (PD) (Eugenio Serra, MD; Demetrio Pittarello, MD; Ivo Tiberio, MD; Ottavia Bond, MD; Elisa Michieletto, MD; Luisa Muraro, MD; Arianna Peralta, MD; Paolo Persona, MD; Enrico Petranzan, MD; Francesco Zarantonello, MD; Alessandro Graziano, MD; Eleonora Piasentini, MD); (3) U.O.C. Anestesia e Rianimazione, Presidio Ospedaliero San Martino, Belluno (BL), AULSS 1 Dolomiti (Lorenzo Bernardi, MD; Roberto Pianon, MD); (4) U.O.C. Anestesia e Rianimazione, Ospedale di Vittorio Veneto, Vittorio Veneto (TV), AULSS 2 Marca Trevigiana (Flavio Badii, MD); (5) U.O.C. Anestesia e Rianimazione, Ospedale di Conegliano, Conegliano (TV), AULSS 2 Marca Trevigiana (Enrico Bosco, MD); (6) U.O.C. Anestesia e Rianimazione, Ospedale di Montebelluna, Montebelluna (TV), AULSS 2 Marca Trevigiana (Moreno Agostini, MD); (7) U.O.C. Anestesia e Rianimazione, Ospedale Ca’ Foncello, Treviso, AULSS 2 Marca Trevigiana (Antonio Farnia, MD; Mario Peta, MD); (8) U.O.C. Anestesia, Rianimazione e Terapia Antalgica, Presidio Ospedaliero di Mirano, Mirano (VE) AULSS 3 Serenissima (Mauro Antonio Calò, MD); (9) U.O.C. Anestesia e Rianimazione, Ospedale SS. Giovanni e Paolo, Venezia, AULSS 3 Serenissima (Marco Meggiolaro, MD); (10) U.O.C. Anestesia e Rianimazione, Ospedale dell'Angelo, Mestre (VE), AULSS 3 Serenissima (Francesco Lazzari, MD; Ivan Martinello, MD; Giorgio Fullin, MD; Francesco Papaccio, MD); (11) U.O.C. Anestesia e Rianimazione, Ospedale di Cittadella, Cittadella (PD), AULSS 6 Euganea (Alfeo Bonato, MD; Camilla Sgarabotto, MD); (12) U.O.C. Anestesia e Rianimazione, Ospedali Riuniti Padova Sud, Monselice (PD), AULSS 6 Euganea (Francesco Montacciani, MD; Parnigotto Alessandra, MD); (13) U.O.C. Anestesia e Rianimazione, Ospedali di Rovigo e Trecenta, Rovigo, AULSS 5 Polesana (Giuseppe Gagliardi, MD; Gioconda Ferraro, MD); (14) U.O.C. Anestesia e Rianimazione, Ospedale Alto Vicentino, Santorso (VI), AULSS 7 Pedemontana (Luigi Ongaro, MD); (15) U.O.C. Anestesia e Rianimazione, Ospedale San Bassiano, Bassano del Grappa (VI), AULSS 7 Pedemontana (Marco Baiocchi, MD); (16) U.O.C Anestesia e Rianimazione, Ospedale di Vicenza, Vicenza (VI), AULSS 8 Berica (Vinicio Danzi, MD); (17) U.O.C. Anestesia e Rianimazione A, Azienda Ospedaliera Universitaria Integrata Verona, Verona (VR) (Paolo Zanatta, MD); (18) U.O.C Anestesia e Rianimazione, Ospedale Magalini di Villafranca, Legnago (VR), AULSS 9 Scaligera (Simonetta Marchiotto, MD; Silvia Bassanini, MD); (19) Dipartimento di Anestesia, Rianimazione e Terapia Antalgica, IRCCS Sacro Cuore-Don Calabria, Negrar (VR) (Massimo Zamperini, MD; Ivan Daroui, MD).
Declarations
Ethics approval and consent to participate
The study was approved by the Institutional Ethical Committee of each participating center (coordinator center approval reference number 4853AO20, while the full list of all approval reference numbers is available in Additional file 2).
Consent for publication
Written informed consent was obtained from each patient according to national regulation.
Competing interests
None related to the present work. PN received royalties from Intersurgical for Helmet Next invention and speaking fees from Philips, Resmed, MSD, Drager and Novartis. The other authors have no other competing interests to declare.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Static compliance and driving pressure are associated with ICU mortality in intubated COVID-19 ARDS
verfasst von
Annalisa Boscolo Nicolò Sella Giulia Lorenzoni Tommaso Pettenuzzo Laura Pasin Chiara Pretto Martina Tocco Enrico Tamburini Alessandro De Cassai Paolo Rosi Enrico Polati Katia Donadello Leonardo Gottin Silvia De Rosa Fabio Baratto Fabio Toffoletto V. Marco Ranieri Dario Gregori Paolo Navalesi COVID-19 VENETO ICU Network
Um herauszufinden, wie gut sich körperliche Übungen dafür eignen, primäre Dysmenorrhö zu lindern, hat eine Studiengruppe sechs verschiedene Verfahren untersucht. Alle wirkten, doch eine Methode war Favorit.
Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.
Betrunken trotz Alkoholabstinenz? Der Fall einer 50-jährigen Patientin zeigt, dass dies möglich ist. Denn die Frau litt unter dem Eigenbrauer-Syndrom, bei dem durch Darmpilze eine alkoholische Gärung in Gang gesetzt wird.
Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.